cStage IA肺癌に対する胸腔鏡下手術の成績—特に標準術式と比較した予後について

Thoracoscopic Surgery for cStagelA Non Small Cell Lung Cancer with Emphasis on its Prognosis

　われわれは，cT1N0M0の末梢型非小細胞肺癌を適応としてnon rib-spreading VATSlobectomy（VATS lobectomy＋ND2a）を施行してきた．cT1N0M0肺癌115例の5年生存率は97.2％であり，胸腔鏡下手術開始前の5年間に標準術式で手術されたcT1N0M0末梢型非小細胞肺癌94例の5年生存率81.1％より有意に良好であった．ただし，腫瘍径20mm以下のpT1N0M0肺癌症例についてみると，胸腔鏡下手術症例78例，標準術式手術症例37例であり，5年生存率はそれぞれ96.4％と94.3％で有意の差は認めなかった．

Since February 1995, we have been treating lung cancer patients with cT1N0M0 cStagelA peripheral non small cell cancer by thoracoscopic surgery. Until May 2001 thoracoscopic surgery (VATS lobectomy +lymphnode dissection) has been applied to 115 such patients. The operation has been performed by a non-rib spreading VATS lobectomy notable for its use of lapprotector H instead of rib-retractors. The 5-year survival rate of the 115 cT1N0M0 lung cancer patients who underwent this procedure was 97.2%.